Wechselwirkungen · Tevagrastim
Tevagrastim 30 MIU/0.5 mL solution for injection/infusion Tevagrastim 48 MIU/0.8 mL solution for injection/infusion · Abschnitt 4.5 · PDF-Seite 12
HOS-209165 · Präparat HOS-154265
The safety and efficacy of filgrastim given on the same day as myelosuppressive cytotoxic chemotherapy have not been definitively established. In view of the sensitivity of rapidly dividing myeloid cells to myelosuppressive cytotoxic chemotherapy, the use of filgrastim is not recommended in the period from 24 hours before to 24 hours after chemotherapy. Preliminary evidence from a small number of patients treated concomitantly with filgrastim and 5-Fluorouracil indicates that the severity of neutropenia may be exacerbated.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluorouracil (HOS-086023)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-15T16:56:00Z · SHA-256 223fde9be465f817df561e3f847f900d7e0edec4fa53511e453c2bed1479e8f6 · Passage c13fe508b31bbca4cf35f6c24c3fca5a1f3d22b23242fa90a50bc8f363292b5d · Zeichen 0–528 im Abschnitt